Leading the charge against Crohn's Disease, these companies are dedicated to research, development, and patient care. Specializing in therapeutic solutions, they strive to alleviate the challenges faced by individuals with Crohn's, offering innovative treatments that aim to manage symptoms, improve quality of life, and advance our understanding of this complex inflammatory condition.
Roche Secures Promising Bowel Disease Therapy The Swiss pharma giant acquired Telavant, a company developing promising treatments for inflammatory bowel disease (IBD) including Crohn's, in a $7.1 billion deal. This acquisition strengthens Roche's pipeline and could lead to new options for patients.
Anti-IL-23s Jockey for Market Leadership The anti-IL-23 drug class, with Janssen's Stelara holding a significant market share, is facing competition from newer entrants like AbbVie's Skyrizi. Interim data suggests these drugs offer comparable efficacy, with cost and delivery options influencing market positioning.
Biosimilars Shake Up the Landscape arrival of adalimumab biosimilars in the US in 2023 has impacted Humira, AbbVie's blockbuster Crohn's treatment, leading to price reductions and increased competition. Ustekinumab biosimilars are expected to enter the market in 2025, further shaking up the dynamics.
Novel Therapies Spark Hope: Companies are actively developing new treatment approaches for Crohn's disease, targeting different aspects of the immune system and disease process.
Eli Lilly's mirikizumab (anti-IL-23p19) and Janssen's Tremfya (guselkumab) are promising candidates with potential for improved efficacy and longer-lasting effects.
List of Crohn’s Disease Key Companies in the Market
Crohns Disease Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)